FIELD: medicine.
SUBSTANCE: invention represents an IL-17-binding antibody or its active fragment. What is also presented is a DNA design coding the antibody, a method of producing the antibody, using the antibody, a pharmaceutical composition, an expression vector.
EFFECT: invention can be effectively used for preparing a drug for treating an IL-17 mediated disease or disorder.
14 cl, 2 dwg, 12 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTERLEUKIN (IL-17) ANTIBODY ANTAGONISTS FOR CANCER TREATMENT | 2007 |
|
RU2430110C2 |
| METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2591083C2 |
| METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2665954C1 |
| METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2582937C2 |
| HUMAN ANTIBODIES TO IL-β1 | 2001 |
|
RU2286351C2 |
| RECOMBINED ANTIBODY TO HUMAN INTERLEUKIN 1β | 2001 |
|
RU2264413C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
| ANTI-IL-17F ANTIBODIES AND METHODS FOR USE THEREOF | 2010 |
|
RU2605318C2 |
| ANTIBODIES RAISED TO HUMAN MCP-1 | 2001 |
|
RU2314316C2 |
| METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
